Menu

Gene Therapy Temporarily Reverses Type 1 Diabetes in Mice

Pancreatic cells engineered to produce insulin did not immediately provoke an immune response.

Jan 4, 2018
Shawna Williams

Human islets were treated with a drug to kill the insulin-making cells, then treated with either an empty virus (left) or a therapeutic virus (right) and grown in a diabetic mouse. The green staining shows insulin-making cells.GEORGE GITTES AND XIANGWEI XIAOResearchers have successfully treated animals with a mouse version of type 1 diabetes by inducing pancreatic cells that don’t normally produce insulin to manufacture the protein, according to a study published today (January 4) in Cell Stem Cell.

The research team, based at the University of Pittsburgh School of Medicine, didn’t expect the experiment to work—since type 1 diabetes arises when the immune system turns on cells that naturally produce insulin, they expected that inflammation would quickly wipe out the engineered cells as well. But instead, the mice thrived for four months before an immune reaction destroyed the cells.

“Type 1 diabetes is an autoimmune disease where the body is reacting to the insulin-producing cells and killing them off and we don’t really know why,” study coauthor George Gittes, a physician scientist at the Children’s Hospital of Pittsburgh, tells Gizmodo. “If you gave patients new insulin cells with a transplant, it will kill them off. If we use gene therapy to get the body to make new insulin-producing cells in the body, logically it should attack those cells too.”

Gittes and his colleagues constructed an adeno-associated virus to carry genetic material that would direct so-called alpha cells in the pancreas to produce insulin—normally the job of beta cells. They then delivered the virus directly to the pancreas of mouse models of type 1 diabetes. The animals’ blood glucose levels stayed at normal levels until the engineered cells were killed off months later. The team is now trying out the strategy in non-human primates, according to a statement, in hopes of eventually bringing it to clinical trials. However, it’s unclear how long the treatment might work in humans, if at all.

“In our mind four months is a long time, especially in mice,” Gittes tells Gizmodo. “We’re hopeful it could be decades in human.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.